Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHSTNASDAQ:CLBSNASDAQ:SAVANASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$6.26-1.4%$6.16$6.25▼$7.38$102.82M0.817,039 shs5,529 shsCLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsSAVACassava Sciences$2.02-1.2%$1.64$1.15▼$42.20$97.34M-2.313.00 million shs247,916 shsSGMTSagimet Biosciences$3.57+1.9%$2.99$1.73▼$7.38$109.36M2.32849,943 shs193,034 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+3.25%-1.55%+21.18%+634,999,900.00%CLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%SAVACassava Sciences-2.86%-3.77%+30.77%-15.00%-90.41%SGMTSagimet Biosciences+2.94%+2.64%+2.34%-5.66%-36.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASAVACassava Sciences3.7944 of 5 stars3.31.00.04.73.30.01.3SGMTSagimet Biosciences2.6669 of 5 stars3.43.00.00.02.32.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.67118.32% UpsideCLBSCaladrius Biosciences 0.00N/AN/AN/ASAVACassava Sciences 2.50Moderate Buy$54.502,604.71% UpsideSGMTSagimet Biosciences 2.80Moderate Buy$22.40528.33% UpsideCurrent Analyst Ratings BreakdownLatest CLBS, SGMT, SAVA, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.004/8/2025BHSTBioHarvest SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/25/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.003/11/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.003/4/2025SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$27.70M3.71N/AN/A($1.08) per share-5.80CLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/ASGMTSagimet Biosciences$2M54.68N/AN/A$3.98 per share0.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.56M-$0.50N/AN/AN/A-76.65%N/A-85.16%N/ACLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/ASAVACassava Sciences-$97.22M-$1.50N/AN/AN/AN/A-88.05%-64.98%8/14/2025 (Estimated)SGMTSagimet Biosciences-$27.88M-$1.76N/AN/AN/AN/A-23.63%-22.91%8/13/2025 (Estimated)Latest CLBS, SGMT, SAVA, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/8/2025Q1 2025SAVACassava SciencesN/A-$0.48N/A-$0.48N/AN/A5/8/2025Q1 2025SGMTSagimet Biosciences-$0.79-$0.56+$0.23-$0.56N/AN/A3/31/2025Q4 2024BHSTBioHarvest Sciences-$0.12-$0.17-$0.05-$0.17$7.24 million$7.17 million3/12/2025Q4 2024SGMTSagimet Biosciences-$0.65-$0.50+$0.15-$0.50N/AN/A3/3/2025Q4 2024SAVACassava Sciences-$0.68-$0.57+$0.11-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.800.48CLBSCaladrius BiosciencesN/A22.3322.33SAVACassava SciencesN/A3.553.55SGMTSagimet BiosciencesN/A38.4138.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACLBSCaladrius Biosciences15.57%SAVACassava Sciences38.05%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACLBSCaladrius Biosciences2.20%SAVACassava Sciences2.40%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/ACLBSCaladrius Biosciences2760.58 million59.25 millionOptionableSAVACassava Sciences3048.31 million43.78 millionOptionableSGMTSagimet Biosciences830.68 million25.28 millionOptionableCLBS, SGMT, SAVA, and BHST HeadlinesRecent News About These CompaniesContrasting Sagimet Biosciences (SGMT) & Its CompetitorsMay 26, 2025 | americanbankingnews.comSagimet Biosciences’ SWOT analysis: denifanstat’s potential in MASH treatmentMay 24, 2025 | investing.comSagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction ...May 24, 2025 | morningstar.comSagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025May 22, 2025 | globenewswire.comSagimet Biosciences (SGMT) Expected to Announce Earnings on WednesdayMay 16, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Purchased by Bridgeway Capital Management LLCMay 13, 2025 | marketbeat.comRenaissance Technologies LLC Sells 220,300 Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT)May 10, 2025 | marketbeat.comSagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 9, 2025 | finanznachrichten.deSagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 8, 2025 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Alyeska Investment Group L.P.May 8, 2025 | marketbeat.comBoothbay Fund Management LLC Has $56,000 Stock Holdings in Sagimet Biosciences Inc. (NASDAQ:SGMT)May 7, 2025 | marketbeat.comSagimet Biosciences Inc. (NASDAQ:SGMT) Shares Sold by Baker BROS. Advisors LPMay 6, 2025 | marketbeat.com138,263 Shares in Sagimet Biosciences Inc. (NASDAQ:SGMT) Bought by 683 Capital Management LLCMay 4, 2025 | marketbeat.comSagimet Biosciences announces presentations at EASL Congress 2025April 25, 2025 | markets.businessinsider.comSagimet Biosciences to Present Phase 2b FASCINATE-2 Study Findings on Denifanstat at EASL Congress 2025April 23, 2025 | quiverquant.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Up 7.11%April 23, 2025 | aaii.comSagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025April 23, 2025 | finance.yahoo.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 14.92%April 7, 2025 | aaii.comWhy Sagimet Biosciences Inc.’s (SGMT) Stock Is Down 12.37%March 31, 2025 | aaii.comSagimet Biosciences Gets Clearance To Initiate Phase 1 Study Of TVB-3567 For Treatment Of AcneMarch 13, 2025 | nasdaq.comSagimet Biosciences Inc.: Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of AcneMarch 12, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLBS, SGMT, SAVA, and BHST Company DescriptionsBioHarvest Sciences NASDAQ:BHST$6.26 -0.09 (-1.42%) As of 11:17 AM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Caladrius Biosciences NASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Cassava Sciences NASDAQ:SAVA$2.02 -0.03 (-1.23%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Sagimet Biosciences NASDAQ:SGMT$3.56 +0.07 (+1.86%) As of 11:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
